Buy Sildalist (Sildenafil 100mg Tadalafil 20/40mg) Online - Unique Dual PDE5 Combo for Severe ED

Fast initial effect from sildenafil

Within 30-60 minutes of taking the combination, sildenafil levels are therapeutic. Men can plan intimacy within this short window.

Extended window from tadalafil

After sildenafil clears (around 6 hours), tadalafil remains active. The combined effect lasts into the next day, allowing spontaneity.

Both agents require sexual arousal

Neither drug produces erection by itself. The dual PDE5 blockade only works when the nitric oxide pathway is activated by sexual stimulation.

Combined side effects

Headache, flushing, nasal congestion, muscle aches — typical PDE5 effects possible from either agent, overlapping in combination use.

Vascular ED

The most common form. Arterial insufficiency reduces blood inflow; venous leak allows outflow during erection. Associated with cardiovascular risk factors (hypertension, diabetes, smoking, obesity).

Neurogenic ED

Nerve pathway damage. Diabetes, pelvic surgery (prostate, bladder, bowel), spinal cord injury, multiple sclerosis. May respond to PDE5 inhibitors depending on nerve integrity.

Hormonal ED

Low testosterone, elevated prolactin, thyroid disorders. Addressing hormonal imbalance often improves ED. Testosterone replacement does not reliably restore erection without PDE5 inhibitor support.

Psychogenic ED

Performance anxiety, depression, relationship issues. Often responds to PDE5 inhibitors because the medication breaks the anxiety-failure cycle.

Mixed ED

Most men have multiple contributors — some vascular, some neural, some psychological, some medication-related. Combined approach often most effective.

Mild-to-moderate ED, good single-agent response

If single-agent sildenafil 50-100 mg or tadalafil 10-20 mg works reliably, there is no benefit from combination. Simpler is better.

Daily or near-daily intimacy pattern

Tadalafil 5 mg daily may fit better. Steady-state continuous coverage without the need for timing around dosing.

Cardiovascular caution

For men with significant cardiovascular disease, single-agent at lowest effective dose is safer than combination. Dual PDE5 effect may raise orthostatic risk, particularly with alpha-blockers.

Clear psychological or hormonal cause

Address the primary issue (depression treatment, testosterone replacement, relationship counseling) rather than escalating PDE5 therapy.

Alpha-blockers (tamsulosin, doxazosin, prazosin)

Significant orthostatic hypotension risk. Combination may be tolerable with careful dose timing (alpha-blocker and PDE5 at least 4 hours apart) but requires caution. For men on alpha-blockers, start with single-agent sildenafil 25 mg or tadalafil 2.5-5 mg to assess tolerance before combination.

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, telithromycin)

Both sildenafil and tadalafil are CYP3A4-metabolized. Strong inhibitors raise blood levels significantly. Combination not recommended with these drugs. If necessary, use single-agent at reduced dose.

Moderate CYP3A4 inhibitors (erythromycin, fluconazole, diltiazem, verapamil)

Modest blood level increase. Use with care. Consider single-agent at lower dose rather than combination.

Antihypertensive medications

Multiple blood pressure drugs can lead to additive hypotension. Discuss with prescriber. Usually manageable with careful dosing in stable hypertension.

Riociguat (soluble guanylate cyclase stimulator)

Contraindicated with any PDE5 inhibitor. Both act on cGMP pathway with dangerous combined effect. Men on riociguat for pulmonary hypertension cannot use PDE5 inhibitors.

LOW RISK — PDE5 inhibitors generally safe

Asymptomatic cardiovascular disease, controlled hypertension, mild stable angina, past uncomplicated MI more than 6-8 weeks ago, mild valvular disease, successful revascularization. These men can usually use PDE5 inhibitors with routine precautions.

INTERMEDIATE RISK — cardiology evaluation first

Three or more cardiovascular risk factors, moderate stable angina, past MI 2-6 weeks ago, heart failure Class II, non-cardiac vascular disease. Need cardiac assessment before PDE5 use. Combination therapy may still be inappropriate even if cleared for single-agent.

HIGH RISK — usually contraindicated

Unstable or refractory angina, uncontrolled hypertension, heart failure Class III-IV, recent MI (less than 2 weeks), high-risk arrhythmia, hypertrophic obstructive cardiomyopathy with symptoms, moderate-to-severe valvular disease. Sexual activity itself is risky; PDE5 inhibitors add to this.

Headache

Most common. Acetaminophen or ibuprofen can help. Hydration is important. Usually resolves as the medication clears. If severe or persistent, try single-agent instead.

Flushing

Facial redness and warmth. Expected vascular effect. Not harmful. Usually brief and cosmetic. Cold water, cool environment can help if bothersome.

Nasal congestion

Vascular dilation in nasal passages. Avoid decongestants with pseudoephedrine. Saline nasal spray can help. Resolves as medication clears.

Dyspepsia / heartburn

Take with light meal rather than empty stomach. Antacid may help. Acid reducers (omeprazole, famotidine) are compatible with Sildalist.

Back and muscle pain (tadalafil-specific)

Usually appears 12-24 hours after dose and lasts 24-48 hours. Acetaminophen or ibuprofen can help. If severe or persistent, consider single-agent sildenafil without tadalafil.

Vision changes (sildenafil-specific)

Mild blue tint, brightness, blurring. Usually brief. Any sudden vision loss is a medical emergency — may indicate NAION (non-arteritic ischemic optic neuropathy) and requires immediate care.

Depression screening

PHQ-9 or similar brief screen. Men with significant depression benefit from treatment (medication, therapy, or both) regardless of ED. Often ED improves with depression treatment.

Sex therapy or couples counseling

Particularly useful for men with psychogenic ED, longstanding relationship patterns, or communication challenges. Sex therapists specialize in sexual dysfunction with evidence-based techniques.

Mindfulness and attention training

Reduces performance anxiety and over-monitoring during intimacy. Growing evidence base for sexual function improvement through mindfulness-based approaches.

Stress management

Chronic stress maintains sympathetic activation that impairs erectile function. Exercise, hobbies, adequate sleep, and relaxation practices all reduce stress physiology.

Reduced hepatic clearance

Older men often have slower CYP3A4 metabolism, prolonging blood levels of both agents. Starting with lower-dose single agent is prudent.

More cardiovascular medications

Multiple antihypertensives, nitrates (contraindicated), alpha-blockers for BPH. Each raises interaction risk with PDE5 inhibitors.

Orthostatic hypotension risk higher

Baroreflex response diminishes with age. Fall risk from dizziness significantly higher. Fractures can be serious.

Different ED picture

Older men more often have significant vascular ED and may need higher PDE5 doses, but also more comorbidities that limit safe dosing. Nuanced balance required.

Allow adequate foreplay time

Rushing to intercourse without foreplay often reduces arousal and medication effectiveness. 15-30 minutes of focused intimacy allows the medication to work with the natural response.

Reduce distractions

Phone off, children settled, work stress set aside. Attention on the partner and the moment supports arousal.

Sensate focus exercises

Structured touching exercises that remove performance pressure. Masters and Johnson developed this technique for ED. Guided by sex therapist or self-directed from reputable resources.

Open partner communication

What feels good, what works, what the partner enjoys. Direct conversation improves arousal more than guessing. Many couples benefit from this communication regardless of ED.

Alcohol

Heavy use directly impairs erection. Combined with Sildalist raises orthostatic risk. Moderate use OK but limit.

Cannabis

Mixed evidence — some men report arousal enhancement, others report ED. No major interaction with PDE5 inhibitors but can affect baseline sexual function. Men who use regularly should mention to prescriber.

Amyl nitrite ("poppers")

Absolutely contraindicated with any PDE5 inhibitor including Sildalist. Same mechanism as nitrates for angina. Life-threatening hypotension possible.

Opioids

Long-term opioid use suppresses testosterone and can cause ED. Prescription opioid use should be mentioned when evaluating ED. PDE5 inhibitors can still work but underlying cause worth addressing.

Strong inhibitors — avoid combination

Ketoconazole, itraconazole, posaconazole, voriconazole (antifungals). Ritonavir, saquinavir, nelfinavir, atazanavir, darunavir (HIV protease inhibitors). Clarithromycin, telithromycin (antibiotics). Nefazodone. Can double or triple PDE5 blood levels.

Moderate inhibitors — use with caution

Erythromycin, fluconazole, diltiazem, verapamil, aprepitant, cimetidine (large doses). Grapefruit and grapefruit juice. Consider single-agent at lower dose rather than combination.

Mild inhibitors — usually safe

Low-dose cimetidine (not routinely used), ciprofloxacin. Minor effect, usually not clinically significant.

Rifampin (antituberculosis)

Strong inducer. Significantly reduces PDE5 blood levels. May render Sildalist ineffective. Alternative ED treatment during rifampin course.

Antiepileptic medications

Carbamazepine, phenytoin, phenobarbital. CYP3A4 inducers that reduce PDE5 effectiveness. Men on these medications may need higher PDE5 doses or alternative treatments.

St John's wort

Herbal CYP3A4 inducer. Reduces PDE5 effectiveness. Men should mention herbal supplement use to prescriber.

History

Onset (gradual vs sudden), context (situational vs global), presence of morning erections, libido status, relationship factors, prior PDE5 trial response. Guides workup priority.

Medical history

Cardiovascular risk factors, diabetes, hypertension, prior surgeries (prostate, pelvic), neurological conditions, mental health, substance use.

Medication review

Antihypertensives (some cause ED), antidepressants (SSRIs commonly), antihistamines, cold medications. Critical for PDE5 interaction assessment.

Physical examination

Blood pressure, heart rate, waist circumference, visual assessment of genitalia, prostate exam if indicated, peripheral vascular assessment.

Laboratory testing

Fasting glucose, HbA1c, lipid panel, testosterone (if hypogonadism suspected), basic metabolic panel. PSA based on age and risk factors.

Headache (most common)

Acetaminophen 500-1000 mg before or at onset. Hydration is essential. For persistent headache, step down to single-agent (sildenafil 50 mg or tadalafil 10 mg) to reduce overall dose.

Flushing

Expected vascular effect. Not harmful but cosmetically bothersome. Cool environment, cold drink can help. Resolves within hours. If severe, consider single-agent at lower dose.

Nasal congestion

Saline nasal spray. Avoid decongestants with pseudoephedrine (vasoconstrictor interaction). Usually resolves within hours. Rarely persistent beyond 24 hours.

Dyspepsia / heartburn

Take with light meal. Antacid (calcium carbonate) can help acute symptoms. Men with chronic reflux may benefit from omeprazole or famotidine around medication use.

Back and muscle pain

Specifically from tadalafil component. Appears 12-24 hours after dose. Acetaminophen or ibuprofen. Hot shower or heating pad. If significant, switch to single-agent sildenafil without tadalafil.

Vision changes

Mild blue haze, brightness, or blurring from sildenafil component. Usually brief and benign. Any sudden vision loss is NAION emergency — immediate care.

Dizziness or lightheadedness

Rise slowly from seated/supine positions. Hydration. Avoid combining with alcohol or multiple antihypertensives. If severe or recurrent, consider discontinuation.

Priapism — erection lasting 4+ hours

Prolonged erection without arousal, or persisting far beyond intercourse. Painful or non-painful. Permanent tissue damage if not treated within 6-8 hours. Emergency room immediately.

Sudden vision loss (NAION)

Non-arteritic ischemic optic neuropathy. Rare but serious. Partial or complete vision loss, often one eye, usually painless. Discontinue medication and seek care immediately.

Sudden hearing loss

Sometimes with ringing (tinnitus) or dizziness. Rare but documented. Discontinue and seek care within 24 hours for best recovery chance.

Chest pain or heart attack symptoms

Chest pressure, pain radiating to arm or jaw, severe shortness of breath. Call emergency services. Tell providers about Sildalist use — this changes nitrate use decisions.

Severe allergic reaction

Facial or throat swelling, difficulty breathing, severe rash. Emergency care immediately.

Sickle cell disease or trait

Highest risk group. PDE5 inhibitor use requires specialist counseling about priapism risk.

Blood cancers (leukemia, multiple myeloma)

Hematologic malignancies can predispose to priapism. Discuss PDE5 use with oncologist.

Prior priapism episode

Any prior priapism, from any cause, raises recurrence risk. PDE5 use should be cautious with specific prescriber discussion.

Combination therapy (dual PDE5)

Theoretical risk slightly higher than single-agent. Though overall still rare, this is one reason single-agent is preferred for most men.

Penile injection therapy

Alprostadil penile injections carry much higher priapism risk than oral PDE5 inhibitors. Men who use both should be especially cautious.

Fast onset priority: sildenafil, avanafil, or Sildalist

For men wanting medication that works within 30-60 minutes. Avanafil fastest but less experience. Sildenafil most studied. Sildalist combines fast and long.

Long window priority: tadalafil or Sildalist

For men wanting 24-36 hour spontaneity. Weekend getaways, uncertain intimacy timing. Tadalafil alone usually sufficient; Sildalist adds fast initial onset.

Daily use priority: tadalafil daily

Low-dose tadalafil 2.5-5 mg daily provides steady-state coverage. Spontaneity without planning. May also help BPH symptoms. Best for frequent intimacy.

Food-flexible priority: tadalafil, avanafil, or Sildalist

For men whose intimacy often follows dinner. Tadalafil and avanafil work regardless of meal. Sildalist works but sildenafil component is affected by fatty meal.

Brand Viagra and Cialis expensive

Pfizer brand Viagra and Lilly brand Cialis typically cost significantly more per pill than generic equivalents. US retail prices particularly high.

Generic sildenafil and tadalafil much cheaper

Both agents are off-patent. Generic versions cost a fraction of brand price. For many men, generic single-agent is the most cost-effective choice.

Sildalist combination intermediate cost

Combines two agents in one tablet. Not FDA approved as fixed-dose; produced by Indian generic manufacturers. Costs more than single-agent generic but less than brand combinations.

Insurance coverage variable

Many US insurance plans do not cover ED medications. Those that do often have significant copays. International markets have variable coverage. Many men pay out of pocket.

Try generic single-agent first

Generic sildenafil 50-100 mg or tadalafil 10-20 mg typically works well and is substantially cheaper than combination.

Occasional vs daily use decision

For infrequent intimacy, on-demand single-agent is most economical. For frequent intimacy, tadalafil 5 mg daily may be more cost-effective than multiple on-demand doses.

Pharmacy price comparison

PDE5 inhibitor prices vary dramatically between pharmacies. Online price comparison tools reveal substantial differences in local pricing.

Multi-pack ordering

Larger quantities often reduce per-pill cost. PDE5 inhibitors have 3+ year shelf life, making bulk purchase practical.

Discount programs and coupons

Pharmacy discount programs (GoodRx, SingleCare, Amazon Pharmacy) can reduce out-of-pocket costs significantly for PDE5 inhibitors.

Prescription documentation

Original pharmacy label or prescription letter. Keep tablets in original bottle. International travel especially important.

Reasonable quantity

Trip supply plus 50% extra. Carrying large quantities (hundreds of pills) can raise customs questions.

Carry in hand luggage

Essential medications belong in hand luggage. Checked bags can delay or be lost.

Standard storage

Room temperature stable. Avoid extreme heat (closed car in sun). Protect from humidity.

Jet lag and dose timing

Sildalist is on-demand medication — take 30-60 minutes before planned intimacy in local time. No complex adjustment needed. The 36-hour tadalafil window means timing is forgiving.

Alcohol-heavy travel destinations

Beach vacations, wine country, cruise ships. Combination tolerates less alcohol than either single agent. Limit to 1 drink around dosing time.

New environment orthostatic risk

Unfamiliar hotel room, dehydration from travel. Rise slowly, hydrate thoroughly. First dose at destination best when well rested.

High-altitude travel

Mountain destinations above 2500m may affect sexual function through hypoxia. PDE5 inhibitors still work. Hydration especially important.

Long flights

Dehydration from air travel. Hydrate well before dose. Avoid combining Sildalist with excess alcohol on the flight.

Choose non-sexual moment

Not during intimacy or immediately before. A calm, relaxed context — evening together, after dinner, during a walk.

Lead with how you feel

"I have been having some issues with erections and it bothers me. I want our intimacy to be as good as possible. I am going to try a medication called Sildalist."

Explain simply

ED is a common medical issue, often with vascular causes. Medication supports the natural response. Takes about 30-60 minutes to work, lasts about 24-36 hours.

Invite partner input

"How do you feel about this? Is there anything that would make intimacy better for you?" Partners usually welcome being part of the discussion.

Problem: inadequate response first attempt

Solution: this is common. Give 4-6 attempts at proper timing, light meal, modest alcohol, good arousal context. Many apparent failures become successes with better conditions.

Problem: timing seems off

Solution: take 30-60 minutes before planned intimacy. If heavy meal planned, take 2 hours before. Avoid taking immediately before (not enough time) or far ahead (sildenafil clearing).

Problem: good at first, less effective later

Solution: assess whether something changed — new medication, more alcohol, increased stress, weight gain, hormonal change. Check testosterone if libido reduced.

Problem: side effects limiting use

Solution: step down to single-agent. Sildenafil alone or tadalafil alone at lower dose. Reduces overall vascular effect while keeping ED treatment.

Problem: expectations not met

Solution: PDE5 inhibitors support response; they do not restore the function of a 20-year-old. Realistic expectations — firm functional erections, satisfactory intercourse — usually achievable. Perfection often not.

Problem: inadequate at any PDE5 dose

Solution: comprehensive ED workup. Hormonal, vascular, nerve testing. Consider penile injections (alprostadil), vacuum erection device, or penile implant surgery for refractory ED.

Alprostadil penile injection

Direct smooth muscle relaxation. Works regardless of nitric oxide pathway. 80-85% response rate. Higher priapism risk; self-injection technique required.

Alprostadil urethral suppository

Non-injection option. Lower response rate than injection but no needle. Transurethral delivery.

Vacuum erection device

Mechanical device creates vacuum, draws blood into penis. Constriction ring maintains erection. Non-medication option; some couples find device acceptable.

Penile implant surgery

For men with severe refractory ED. Inflatable or malleable prostheses. High patient and partner satisfaction. Permanent and definitive but surgical.

25+ years sildenafil experience

Massive post-marketing experience since 1998. No major new safety signals have emerged over this long follow-up. Side effect profile remains stable.

20+ years tadalafil experience

Approved 2003. Long-term safety confirmed. Daily low-dose use (2.5-5 mg) also studied extensively. Favorable safety profile.

No tolerance development

Unlike some medications, PDE5 inhibitors do not develop tolerance with continued use. Men can use same dose for years without needing escalation.

No cardiovascular risk increase

Despite initial concerns, long-term follow-up shows no increase in heart attack or stroke risk with PDE5 inhibitor use. In fact, some studies suggest cardiovascular benefit through improved endothelial function.

Annual medical review

Cardiovascular status, medication list reconciliation, side effects assessment, continued response verification.

Dose optimization

Consider whether combination still needed or whether single-agent at optimal dose would be sufficient. Many men on combination can step down.

Life circumstances changes

New partner, change in frequency, new medications, new health conditions — each warrant reassessment of treatment approach.

Cardiovascular risk evolution

Aging may bring new cardiac issues. New angina or heart failure diagnosis may contraindicate nitrates, requiring PDE5 reassessment.

Myth: PDE5 inhibitors cause erection automatically

Reality: Both sildenafil and tadalafil require sexual arousal to produce erection. The medication amplifies the natural response; it does not create response from nothing.

Myth: combination is twice as effective as single-agent

Reality: PDE5 inhibition at maximum single-agent dose is already essentially complete. Combination offers kinetic flexibility (fast + long), not doubled potency. For most men, optimized single-agent works as well.

Myth: once ED starts, you need the pill forever

Reality: Some ED is reversible (lifestyle, cardiovascular treatment, mental health, hormonal). PDE5 inhibitors do not cause dependence. Many men who address underlying contributors can reduce or stop medication.

Myth: PDE5 inhibitors cause heart attack

Reality: Long-term follow-up shows no increase in heart attack risk. The deaths associated with PDE5 inhibitors are usually from either sexual activity itself (physical exertion) or nitrate interactions. Medication alone does not raise cardiac event risk.

Myth: taking more pills works better

Reality: Maximum single tablet dose. Taking two doses raises side effects without improving effect. Tadalafil especially requires 72-hour interval between doses.

Myth: natural supplements work as well

Reality: Rigorous studies of yohimbine, L-arginine, horny goat weed, and similar supplements show minimal to no benefit for ED. Herbal supplements marketed for ED often contain undisclosed PDE5 inhibitors or other active ingredients with no quality control.

Myth: ED means you are not attracted to partner

Reality: ED is predominantly physiological (vascular, nerve, hormonal) rather than attraction-related. Partners who understand this are relieved. Treatment supports the physiology; attraction itself is a separate dimension.

PDE5 inhibitors are effective

60-80% of men respond to appropriate PDE5 therapy with proper timing and context.

ED often indicates cardiovascular risk

ED precedes cardiac symptoms by 3-5 years. Treatment opportunity for cardiovascular prevention.

Lifestyle improvements amplify medication benefit

Exercise, weight loss, smoking cessation, diabetes control all improve response.

Nitrate interaction is real and dangerous

The single most important safety consideration. Absolute contraindication must be respected.

New nitrate medication

If prescribed nitrates for cardiac condition, PDE5 inhibitors become contraindicated. Discontinue permanently and discuss alternative ED management.

Significant adverse event

NAION, hearing loss, priapism, severe allergic reaction. Permanent discontinuation. Alternative ED approaches needed.

No need (ED resolved)

Some men whose ED was situational, psychogenic, or related to reversible factors (weight loss, cardiovascular treatment, depression resolution) may no longer need medication.

Switch to different approach

Moving to single-agent at optimal dose, penile injection, vacuum device, or implant. Discontinue combination for alternative.

End of life planning

In palliative care context, ED medications may be discontinued as treatment goals shift.

Hypertension

Very common and worsens ED through vascular effects. Control supports response to PDE5. Some BP medications contribute to ED (beta-blockers, thiazide diuretics); others neutral or helpful.

Diabetes

Significantly increases ED risk through vascular and nerve effects. Glycemic control improves response to PDE5 inhibitors. HbA1c monitoring important.

Dyslipidemia

High cholesterol contributes to vascular ED. Statin therapy may actually improve ED through endothelial function. Lipid management supports PDE5 response.

Benign prostatic hyperplasia

BPH and ED often coexist in older men. Daily low-dose tadalafil can address both. Alpha-blocker for BPH may interact with Sildalist combination.

Hypogonadism

Low testosterone affects libido and may reduce PDE5 response. Testosterone replacement combined with PDE5 inhibitor often works better than either alone.

Depression and anxiety

Common and often undertreated. Both contribute to ED. Treatment of mental health often improves ED. Some antidepressants cause ED — discussion with prescriber for best choice.

Sildenafil 25+ years

Approved 1998. Hundreds of millions of patient-years of exposure. Safety profile stable with continued use.

Tadalafil 20+ years

Approved 2003. Extensive on-demand and daily-dose data. Long-term safety confirmed.

No new safety signals

Despite extensive post-marketing surveillance, no major new safety concerns have emerged with long-term use.

No tolerance or dependence

Response remains stable with continued use. No escalation of dose needed over years. No withdrawal on discontinuation.

Annual medical review

Cardiovascular status, blood pressure, medication list reconciliation, continued treatment benefit. New nitrate contraindication must be identified.

Dose optimization

Combination therapy may not be needed indefinitely. Consider whether optimized single-agent would suffice. Many men can step down over years.

Life circumstances review

New partner, change in frequency, new health conditions — each warrant reassessment.

Alternative consideration

If PDE5 response has diminished or side effects increased, alternatives (injections, implants, lifestyle) may fit better than continued combination.

Nitrate medication use

Any form of nitrate — nitroglycerin, isosorbide dinitrate or mononitrate, amyl nitrite. Fatal hypotension risk. Absolute contraindication for both PDE5 agents in Sildalist.

Riociguat (soluble guanylate cyclase stimulator)

For pulmonary hypertension. Dangerous hypotension with any PDE5 inhibitor. Alternative ED treatment needed for men on riociguat.

Hypersensitivity to sildenafil or tadalafil

Known allergy to either component or any inactive ingredient.

Severe cardiovascular disease

Recent MI (within 2 weeks), unstable angina, uncontrolled hypertension, heart failure Class III-IV, hypertrophic obstructive cardiomyopathy with symptoms, significant arrhythmia. Sexual activity itself is risky; PDE5 inhibitors add to this.

History of NAION

Prior non-arteritic ischemic optic neuropathy from any PDE5 inhibitor use. Recurrent NAION risk with continued use. Alternative ED treatment required.

Retinitis pigmentosa

Inherited retinal disorder with altered PDE6 expression. Theoretical risk of vision worsening with PDE5 inhibitors. Avoid or use with ophthalmology input.

Not for women, children, or adolescents

Not indicated or approved for use under 18 or in women.

Alpha-blockers (tamsulosin, doxazosin)

Significant orthostatic hypotension risk. Separate dosing by 4+ hours. Start with single-agent at low dose before combination.

Strong CYP3A4 inhibitors

Ketoconazole, itraconazole, ritonavir, clarithromycin. Avoid combination; use single-agent at reduced dose if essential.

Severe hepatic impairment

Child-Pugh class C. Significantly reduced clearance. Use alternative treatment.

Severe renal impairment

GFR less than 30. Specialist review needed; dose adjustment required.

Priapism risk conditions

Sickle cell disease, leukemia, multiple myeloma, prior priapism. Specialist counseling before PDE5 use.

Age over 75

Limited combination data; orthostatic risk higher. Prefer single-agent at low dose.